RxDoctor Payments Data

Deepak Patel, MD

Internal Medicine · Corsicana, TXNPI 1114989910

Payments from drug & device makers

$759in general payments, 2019–2025

Across 42 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$139
  • E.r. Squibb & Sons, L.L.C.$59
  • Inspire Medical Systems, Inc.$57
  • Novartis$51
  • GSK$51
  • Cook Medical LLC$40
  • plus $361 from 14 others

What the payments were for

  • Food & beverage$759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$759 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$169,930
Medicare patients
348
Services billed
1,735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban379$114,236
OzempicSemaglutide55$72,786
Tresiba Flextouch U-200Insulin Degludec81$69,254
XareltoRivaroxaban156$53,387
Bydureon BciseExenatide Microspheres97$42,630
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$42,225
XifaxanRifaximin24$36,684
MyrbetriqMirabegron114$33,188
JanuviaSitagliptin Phosphate73$25,213
JardianceEmpagliflozin77$23,291
TrulicityDulaglutide32$21,755
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$20,668
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$20,593
TradjentaLinagliptin62$19,602
Lagevrio (Eua)Molnupiravir15$15,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$114,236379 claims
Novo NordiskOzempic, Levemir$139$79,62971 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$51$53,44684 claims
Johnson & JohnsonXarelto$17$53,387156 claims
Boehringer IngelheimJardiance, Tradjenta$26$42,893139 claims
Lilly USA, LLCTrulicity$30$21,75532 claims
NovartisEntresto$51$8,59725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Corsicana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →